SB 281832
Latest Information Update: 05 Nov 2002
At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases; Rheumatoid arthritis; Vascular restenosis
Most Recent Events
- 05 Nov 2002 Discontinued - Phase-I for Inflammatory bowel disease in United Kingdom (unspecified route)
- 05 Nov 2002 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (unspecified route)
- 05 Nov 2002 Discontinued - Preclinical for Vascular restenosis in USA (PO)